217 related articles for article (PubMed ID: 26797935)
1. Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents.
Podda MG; Luksch R; Puma N; Gandola L; Morosi C; Terenziani M; Ferrari A; Casanova M; Spreafico F; Meazza C; Catania S; Schiavello E; Biassoni V; Chiaravalli S; Massimino M
Tumori; 2016; 102(1):84-8. PubMed ID: 26797935
[TBL] [Abstract][Full Text] [Related]
2. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
[TBL] [Abstract][Full Text] [Related]
3. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
4. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
5. Oral etoposide for recurrent/progressive sarcomas of childhood.
Kebudi R; Görgün O; Ayan I
Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.
Owens C; Laurence V; Benboubker L; Defachelles AS; Cupissol D; Rubie H; Brisse H; Rey A; Ollivier L; Couanet D; Baunin C; Aït-Oukhatar CM; Oberlin O
Cancer Chemother Pharmacol; 2013 Feb; 71(2):399-404. PubMed ID: 23161409
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Korones DN; Smith A; Foreman N; Bouffet E
Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
[TBL] [Abstract][Full Text] [Related]
8. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
[TBL] [Abstract][Full Text] [Related]
9. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
10. Response of recurrent medulloblastoma to low-dose oral etoposide.
Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
[TBL] [Abstract][Full Text] [Related]
11. Oral etoposide for refractory and relapsed neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 1999 Oct; 17(10):3221-5. PubMed ID: 10506622
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
14. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS].
Fröhlich B; Ahrens S; Burdach S; Klingebiel T; Ladenstein R; Paulussen M; Zoubek A; Jürgens H
Klin Padiatr; 1999; 211(4):284-90. PubMed ID: 10472563
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.
Farhat R; Raad R; Khoury NJ; Feghaly J; Eid T; Muwakkit S; Abboud M; El-Solh H; Saab R
J Pediatr Hematol Oncol; 2013 Jul; 35(5):356-60. PubMed ID: 23042020
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.
Evans SR; Krown SE; Testa MA; Cooley TP; Von Roenn JH
J Clin Oncol; 2002 Aug; 20(15):3236-41. PubMed ID: 12149296
[TBL] [Abstract][Full Text] [Related]
17. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
[TBL] [Abstract][Full Text] [Related]
19. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors.
Cooper MA; Einhorn LH
J Clin Oncol; 1995 May; 13(5):1167-9. PubMed ID: 7738621
[TBL] [Abstract][Full Text] [Related]
20. Relapse after high-dose therapy in relapsed Ewing's tumor patients: effects of maintenance chemotherapy in two selected patients?
Laws HJ; van Kaick B; Pape H; Paulussen M; Göbel U
Onkologie; 2003 Dec; 26(6):573-7. PubMed ID: 14709933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
